Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1981 1
1982 3
1983 6
1984 8
1985 11
1986 7
1987 16
1988 10
1989 10
1990 12
1991 13
1992 23
1993 32
1994 23
1995 27
1996 26
1997 40
1998 36
1999 48
2000 55
2001 64
2002 92
2003 85
2004 115
2005 136
2006 175
2007 204
2008 223
2009 246
2010 353
2011 370
2012 480
2013 573
2014 647
2015 728
2016 791
2017 793
2018 960
2019 1100
2020 1347
2021 1557
2022 1810
2023 1730
2024 1708
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,952 results

Results by year

Filters applied: . Clear all
Page 1
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y, Yang R, Yu G, Gong Y, Zhao J, Fan Y, Liu Q, Cao L, Yao Y, Liu Y, Li X, Wu J, He Z, Lu K, Jiang L, Hu C, Zhao W, Zhang B, Shi W, Zhang X, Cheng Y; CAPSTONE-1 Study Group. Wang J, et al. Among authors: xu f. Lancet Oncol. 2022 Jun;23(6):739-747. doi: 10.1016/S1470-2045(22)00224-8. Epub 2022 May 13. Lancet Oncol. 2022. PMID: 35576956 Clinical Trial.
Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002).
Hua X, Bi XW, Zhao JL, Shi YX, Lin Y, Wu ZY, Zhang YQ, Zhang LH, Zhang AQ, Huang H, Liu XM, Xu F, Guo Y, Xia W, Hong RX, Jiang KK, Xue C, An X, Zhong YY, Wang SS, Huang JJ, Yuan ZY. Hua X, et al. Among authors: xu f. Clin Cancer Res. 2022 Feb 15;28(4):637-645. doi: 10.1158/1078-0432.CCR-21-3435. Clin Cancer Res. 2022. PMID: 34810217 Free PMC article. Clinical Trial.
The CD112R/CD112 axis: a breakthrough in cancer immunotherapy.
Zeng T, Cao Y, Jin T, Tian Y, Dai C, Xu F. Zeng T, et al. Among authors: xu f. J Exp Clin Cancer Res. 2021 Sep 10;40(1):285. doi: 10.1186/s13046-021-02053-y. J Exp Clin Cancer Res. 2021. PMID: 34507594 Free PMC article. Review.
Targeting a vulnerable septum-hippocampus cholinergic circuit in a critical time window ameliorates tau-impaired memory consolidation.
Wu D, Yu N, Gao Y, Xiong R, Liu L, Lei H, Jin S, Liu J, Liu Y, Xie J, Liu E, Zhou Q, Liu Y, Li S, Wei L, Lv J, Yu H, Zeng W, Zhou Q, Xu F, Luo MH, Zhang Y, Yang Y, Wang JZ. Wu D, et al. Among authors: xu f. Mol Neurodegener. 2023 Apr 14;18(1):23. doi: 10.1186/s13024-023-00614-7. Mol Neurodegener. 2023. PMID: 37060096 Free PMC article.
14,952 results
You have reached the last available page of results. Please see the User Guide for more information.